Patents by Inventor Changshou Gao
Changshou Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8409568Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.Type: GrantFiled: July 15, 2010Date of Patent: April 2, 2013Assignee: MedImmune, LLCInventors: Changshou Gao, Herren Wu
-
Publication number: 20130053322Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: ApplicationFiled: February 15, 2011Publication date: February 28, 2013Applicant: Medlmmune, LLCInventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
-
Publication number: 20120213705Abstract: Fc regions useful for site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such Fc regions are also provided.Type: ApplicationFiled: June 21, 2010Publication date: August 23, 2012Applicant: MEDIMMUNE, LLCInventors: Nazzareno Dimasi, Changshou Gao
-
Patent number: 8153131Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: August 3, 2009Date of Patent: April 10, 2012Assignee: MedImmune, LLCInventors: Herren Wu, Christian Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Patent number: 8129130Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: March 18, 2011Date of Patent: March 6, 2012Assignees: The Feinstein Institute for Medical Research, MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20110287023Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: March 18, 2011Publication date: November 24, 2011Applicants: Critical Therapeutics, Inc., MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20110280892Abstract: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.Type: ApplicationFiled: December 21, 2010Publication date: November 17, 2011Applicants: MedImmune, LLC, Seattle Genetics, Inc.Inventors: Michael S. Kinch, Herren Wu, Christine Bachy, David Tice, Changshou Gao, Peter D. Senter
-
Patent number: 7964706Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: November 27, 2006Date of Patent: June 21, 2011Assignee: MedImmune, LLCInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian
-
Publication number: 20110076752Abstract: The present invention relates to antibodies or antibody fragments that may be displayed on the extracellular surface of the plasma membrane when expressed in a host cell. The present invention provides libraries comprising a plurality of plasma membrane displayed antibodies and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.Type: ApplicationFiled: February 8, 2008Publication date: March 31, 2011Applicant: MEDIMMUNE, LLCInventors: Herren Wu, Changshou Gao
-
Publication number: 20110059100Abstract: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL-13 mediated inflammation.Type: ApplicationFiled: January 9, 2009Publication date: March 10, 2011Applicants: MEDIMMUNE, LLC, YALE UNIVERSITYInventors: Jennifer L. Reed, Wendy I. White, Anthony Coyle, Alexander Kozhich, Jack Elias, Nanci Donacki, Changshou Gao, Herren Wu
-
Publication number: 20110033378Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.Type: ApplicationFiled: January 16, 2009Publication date: February 10, 2011Applicant: Medlmmune, LLC.Inventors: Nazzareno Dimasi, Changshou Gao, Herren Wu
-
Publication number: 20100331208Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.Type: ApplicationFiled: July 15, 2010Publication date: December 30, 2010Applicant: MEDIMMUNE, LLCInventors: Changshou GAO, Herren WU
-
Publication number: 20100233173Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.Type: ApplicationFiled: March 5, 2010Publication date: September 16, 2010Applicant: MEDIMMUNE, LLCInventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI
-
Patent number: 7790655Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.Type: GrantFiled: October 13, 2006Date of Patent: September 7, 2010Assignee: MedImmune, LLCInventors: Changshou Gao, Herren Wu
-
Publication number: 20100203045Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.Type: ApplicationFiled: December 4, 2009Publication date: August 12, 2010Applicant: MEDIMMUNE, LLCInventors: Herren Wu, Changshou Gao
-
Publication number: 20100061987Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: August 3, 2009Publication date: March 11, 2010Applicant: MedImmune, LLCInventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Patent number: 7659374Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.Type: GrantFiled: August 15, 2005Date of Patent: February 9, 2010Assignee: MedImmune, LLCInventors: Herren Wu, Changshou Gao
-
Patent number: 7585504Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: October 21, 2005Date of Patent: September 8, 2009Assignee: MedImmune, LLCInventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Publication number: 20090169546Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: November 27, 2006Publication date: July 2, 2009Applicants: MEDIMMUNE, LLC, CRITICAL THERAPEUTICSInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20090155275Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.Type: ApplicationFiled: July 30, 2008Publication date: June 18, 2009Applicant: MEDIMMUNE, LLCInventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI